Umifenovir

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Umifenovir (trade name: Arbidol) is a broad-spectrum antiviral approved for use in China and Russia for the treatment of influenza.

Preliminary studies have shown that umifenovir has activity against Coxsackie B viruses. Umifenovir was found to have antiviral activity against Coxsackie virus B5 (CVB5) in vitro and in vivo, having both a cytopathic effect as well as directly reducing intracellular RNA. Orally administered umifenovir reduced virus in the lungs and heart, as well as mortality in an animal model of acute infection.[1] A separate study found antiviral activity against Coxsackie B3,[2] and a third study found umifenovir inhibited Coxsackie B4 in part by reducing the expression of IL-10 (by preventing p38-MK2 complex from exiting the nucleus).[3]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]


The information provided at this site is not intended to diagnose or treat any illness.

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history